Klaus Okkenhaug

List of Publications by Year
in descending order

118 papers	17,742 citations	26630 56 h-index	21540 114 g-index
130 all docs	130 docs citations	130 times ranked	21359 citing authors

#	Article	IF	Citations
1	Requirement of <i>bic/microRNA-155</i> for Normal Immune Function. Science, 2007, 316, 608-611.	12.6	1,786
2	Cellular Function of Phosphoinositide 3-Kinases: Implications for Development, Immunity, Homeostasis, and Cancer. Annual Review of Cell and Developmental Biology, 2001, 17, 615-675.	9.4	1,047
3	Ribosomal Protein S6 Kinase 1 Signaling Regulates Mammalian Life Span. Science, 2009, 326, 140-144.	12.6	1,009
4	Impaired B and T Cell Antigen Receptor Signaling in p110delta PI 3-Kinase Mutant Mice. Science, 2002, 297, 1031-4.	12.6	836
5	PI3K in lymphocyte development, differentiation and activation. Nature Reviews Immunology, 2003, 3, 317-330.	22.7	690
6	Phosphoinositide 3-Kinase Î´ Gene Mutation Predisposes to Respiratory Infection and Airway Damage. Science, 2013, 342, 866-871.	12.6	541
7	PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells. Journal of Experimental Medicine, 2012, 209, 2441-2453.	8.5	518
8	Evidence for lifespan extension and delayed ageâ€"related biomarkers in insulin receptor substrate 1 null mice. FASEB Journal, 2008, 22, 807-818.	0.5	487
9	Ionic immune suppression within the tumour microenvironment limits T cell effector function. Nature, 2016, 537, 539-543.	27.8	479
10	Inactivation of PI(3)K p110Î´ breaks regulatory T-cell-mediated immune tolerance to cancer. Nature, 2014, 510, 407-411.	27.8	450
11	Critical role for the p110Î± phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature, 2006, 441, 366-370.	27.8	439
12	Clinical spectrum and features of activated phosphoinositide 3-kinase Î´ syndrome: AÂlarge patient cohort study. Journal of Allergy and Clinical Immunology, 2017, 139, 597-606.e4.	2.9	377
13	Essential role for the p110Î´ phosphoinositide 3-kinase in the allergic response. Nature, 2004, 431, 1007-1011.	27.8	369
14	Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking. Nature Immunology, 2008, 9, 513-521.	14.5	364
15	Cutting Edge: The Foxp3 Target miR-155 Contributes to the Development of Regulatory T Cells. Journal of Immunology, 2009, 182, 2578-2582.	0.8	350
16	Signaling by the Phosphoinositide 3-Kinase Family in Immune Cells. Annual Review of Immunology, 2013, 31, 675-704.	21.8	349
17	The p110Î² isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110Î³. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 8292-8297.	7.1	317
18	Cutting Edge: The Phosphoinositide 3-Kinase p110Î´ Is Critical for the Function of CD4+CD25+Foxp3+ Regulatory T Cells. Journal of Immunology, 2006, 177, 6598-6602.	0.8	280

#	Article	IF	Citations
19	Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood, 2005, 106, 1432-1440.	1.4	274
20	PI3KÎ´ and primary immunodeficiencies. Nature Reviews Immunology, 2016, 16, 702-714.	22.7	259
21	PI3K inhibitors in inflammation, autoimmunity and cancer. Current Opinion in Pharmacology, 2015, 23, 82-91.	3.5	258
22	Protein Kinase B Controls Transcriptional Programs that Direct Cytotoxic T Cell Fate but Is Dispensable for T Cell Metabolism. Immunity, 2011, 34, 224-236.	14.3	235
23	PI3K inhibitors are finally coming of age. Nature Reviews Drug Discovery, 2021, 20, 741-769.	46.4	222
24	BACH2 regulates CD8+ T cell differentiation by controlling access of AP-1 factors to enhancers. Nature Immunology, 2016, 17, 851-860.	14.5	221
25	Cutting Edge: Differential Roles for Phosphoinositide 3-Kinases, p110Î³ and p110Î´, in Lymphocyte Chemotaxis and Homing. Journal of Immunology, 2004, 173, 2236-2240.	0.8	217
26	Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy. Cancer Discovery, 2016, 6, 1090-1105.	9.4	217
27	Key role of the p110Î´ isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110Î´ function in B cells. Blood, 2006, 107, 642-650.	1.4	202
28	Phosphoinositide 3-Kinase Activity in T Cells Regulates the Magnitude of the Germinal Center Reaction. Journal of Immunology, 2010, 185, 4042-4052.	0.8	200
29	Socs1 binds to multiple signalling proteins and suppresses Steel factor-dependent proliferation. EMBO Journal, 1999, 18, 904-915.	7.8	192
30	The p110Î´ Isoform of Phosphoinositide 3-Kinase Controls Clonal Expansion and Differentiation of Th Cells. Journal of Immunology, 2006, 177, 5122-5128.	0.8	192
31	A point mutation in CD28 distinguishes proliferative signals from survival signals. Nature Immunology, 2001, 2, 325-332.	14.5	187
32	Regulatory T Cell Migration Is Dependent on Glucokinase-Mediated Glycolysis. Immunity, 2017, 47, 875-889.e10.	14.3	181
33	The PI3K Isoforms p110Î± and p110Î´ Are Essential for Preâ€"B Cell Receptor Signaling and B Cell Development. Science Signaling, 2010, 3, ra60.	3.6	179
34	PI3K p110Î´ regulates T-cell cytokine production during primary and secondary immune responses in mice and humans. Blood, 2010, 115, 2203-2213.	1.4	174
35	P-Rex1 Regulates Neutrophil Function. Current Biology, 2005, 15, 1867-1873.	3.9	161
36	PI3KÎ² Plays a Critical Role in Neutrophil Activation by Immune Complexes. Science Signaling, 2011, 4, ra23.	3.6	130

#	Article	IF	Citations
37	Gene Targeting in Mice: A Review. Methods in Molecular Biology, 2013, 1064, 315-336.	0.9	128
38	Obesity-Induced Metabolic Stress Leads to Biased Effector Memory CD4 + T Cell Differentiation via PI3K p110Î´-Akt-Mediated Signals. Cell Metabolism, 2017, 25, 593-609.	16.2	124
39	CD28 provides T-cell costimulation and enhances PI3K activity at the immune synapse independently of its capacity to interact with the p85/p110 heterodimer. Blood, 2008, 111, 1464-1471.	1.4	121
40	Antigen receptor signalling: a distinctive role for the p110Î´ isoform of PI3K. Trends in Immunology, 2007, 28, 80-87.	6.8	114
41	Inactivation of PI3KÎ³ and PI3KÎ´ distorts T-cell development and causes multiple organ inflammation. Blood, 2007, 110, 2940-2947.	1.4	113
42	MAPK, Phosphatidylinositol 3-Kinase, and Mammalian Target of Rapamycin Pathways Converge at the Level of Ribosomal Protein S6 Phosphorylation to Control Metabolic Signaling in CD8 T Cells. Journal of Immunology, 2009, 183, 7388-7397.	0.8	108
43	Role of the phosphoinositide 3â€kinase p110Î´ in generation of typeâ€„2 cytokine responses and allergic airway inflammation. European Journal of Immunology, 2007, 37, 416-424.	2.9	106
44	The PI3K p110Î´ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function. Journal of Immunology, 2019, 202, 1397-1405.	0.8	104
45	Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy. JCI Insight, 2018, 3, .	5.0	90
46	Class I Phosphoinositide 3-Kinase p110Î² Is Required for Apoptotic Cell and FcÎ³ Receptor-mediated Phagocytosis by Macrophages. Journal of Biological Chemistry, 2003, 278, 38437-38442.	3.4	83
47	The p110Î´ Isoform of Phosphatidylinositol 3-Kinase Controls Susceptibility to <i>Leishmania major</i> by Regulating Expansion and Tissue Homing of Regulatory T Cells. Journal of Immunology, 2009, 183, 1921-1933.	0.8	83
48	The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases. Open Rheumatology Journal, 2012, 6, 245-258.	0.2	82
49	Physiologic and aberrant regulation of memory T-cell trafficking by the costimulatory molecule CD28. Blood, 2007, 109, 2968-2977.	1.4	74
50	p110Â and p110Â isoforms of phosphoinositide 3-kinase differentially regulate natural killer cell migration in health and disease. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 5795-5800.	7.1	74
51	CCL21 mediates CD4+ T-cell costimulation via a DOCK2/Rac-dependent pathway. Blood, 2009, 114, 580-588.	1.4	74
52	The PI3K p110Î´ Regulates Expression of CD38 on Regulatory T Cells. PLoS ONE, 2011, 6, e17359.	2.5	73
53	Blockade of Phosphatidylinositol 3-Kinase (PI3K)Î´ or PI3KÎ³ Reduces IL-17 and Ameliorates Imiquimod-Induced Psoriasis-like Dermatitis. Journal of Immunology, 2012, 189, 4612-4620.	0.8	71
54	Genetic or pharmaceutical blockade of p110Î´ phosphoinositide 3-kinase enhances IgE production. Journal of Allergy and Clinical Immunology, 2008, 122, 811-819.e2.	2.9	67

#	Article	IF	Citations
55	Grb2 Forms an Inducible Protein Complex with CD28 through a Src Homology 3 Domain-Proline Interaction. Journal of Biological Chemistry, 1998, 273, 21194-21202.	3.4	63
56	Cross Talk between Phosphatidylinositol 3-Kinase and Cyclic AMP (cAMP)-Protein Kinase A Signaling Pathways at the Level of a Protein Kinase B/Î²-Arrestin/cAMP Phosphodiesterase 4 Complex. Molecular and Cellular Biology, 2010, 30, 1660-1672.	2.3	61
57	CD28 Regulates the Translation of Bcl-xL via the Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Pathway. Journal of Immunology, 2005, 174, 180-194.	0.8	58
58	Ig gene-like molecule CD31 plays a nonredundant role in the regulation of T-cell immunity and tolerance. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 19461-19466.	7.1	57
59	PI3KÎ´ hyper-activation promotes development of BÂcells that exacerbate Streptococcus pneumoniae infection in an antibody-independent manner. Nature Communications, 2018, 9, 3174.	12.8	56
60	PI3Ks in Lymphocyte Signaling and Development. Current Topics in Microbiology and Immunology, 2010, 346, 57-85.	1.1	55
61	Tumors induce de novo steroid biosynthesis in T cells to evade immunity. Nature Communications, 2020, 11, 3588.	12.8	54
62	T cell receptorâ€“induced phosphoinositide-3-kinase p110Î´ activity is required for T cell localization to antigenic tissue in mice. Journal of Clinical Investigation, 2008, 118, 1154-64.	8.2	49
63	The transcription factor BACH2 promotes tumor immunosuppression. Journal of Clinical Investigation, 2016, 126, 599-604.	8.2	49
64	Cowden's syndrome with immunodeficiency. Journal of Medical Genetics, 2015, 52, 856-859.	3.2	48
65	Role of the p110Î´ PI 3-kinase in integrin and ITAM receptor signalling in platelets. Platelets, 2005, 16, 191-202.	2.3	47
66	BACH2 drives quiescence and maintenance of resting Treg cells to promote homeostasis and cancer immunosuppression. Journal of Experimental Medicine, 2020, 217, .	8.5	47
67	Cholesterol metabolism drives regulatory B cell IL-10 through provision of geranylgeranyl pyrophosphate. Nature Communications, 2020, 11, 3412.	12.8	47
68	Idelalisibâ€"targeting PI3KÎ´ in patients with B-cell malignancies. Nature Reviews Clinical Oncology, 2014, 11, 184-186.	27.6	46
69	PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL). Current Topics in Microbiology and Immunology, 2015, 393, 123-142.	1.1	46
70	CCR8 marks highly suppressive Treg cells within tumours but is dispensable for their accumulation and suppressive function. Immunology, 2021, 163, 512-520.	4.4	46
71	Requirement for Phosphoinositide 3-Kinase p110Î´ Signaling in B Cell Antigen Receptor-Mediated Antigen Presentation. Journal of Immunology, 2007, 178, 2328-2335.	0.8	45
72	PI3K induces B-cell development and regulates B cell identity. Scientific Reports, 2018, 8, 1327.	3.3	43

#	Article	IF	Citations
73	IL-21 Promotes CD4 T Cell Responses by Phosphatidylinositol 3-Kinaseâ€“Dependent Upregulation of CD86 on B Cells. Journal of Immunology, 2014, 192, 2195-2201.	0.8	42
74	Does the PI3K pathway promote or antagonize regulatory T cell development and function?. Frontiers in Immunology, 2012, 3, 244.	4.8	38
75	Phosphoinositide 3-kinase Î´ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors. JCI Insight, 2018, 3, .	5.0	38
76	Rules of engagement: distinct functions for the four class I PI3K catalytic isoforms in immunity. Annals of the New York Academy of Sciences, 2013, 1280, 24-26.	3.8	37
77	Intermittent PI3KÎ´ inhibition sustains anti-tumour immunity and curbs irAEs. Nature, 2022, 605, 741-746.	27.8	36
78	Gene-targeting reveals physiological roles and complex regulation of the phosphoinositide 3-kinases. Archives of Biochemistry and Biophysics, 2003, 414, 13-18.	3.0	34
79	A two-signal model for T cell trafficking. Trends in Immunology, 2007, 28, 267-273.	6.8	34
80	PI3KÎ´ Regulates the Magnitude of CD8+ T Cell Responses after Challenge with <i>Listeria monocytogenes</i>. Journal of Immunology, 2015, 195, 3206-3217.	0.8	32
81	Pten Loss in CD4 T Cells Enhances Their Helper Function but Does Not Lead to Autoimmunity or Lymphoma. Journal of Immunology, 2012, 188, 5935-5943.	0.8	31
82	<scp>PI</scp> 3â€kinase delta enhances axonal <scp>PIP</scp> ₃ to support axon regeneration in the adult <scp>CNS</scp>. EMBO Molecular Medicine, 2020, 12, e11674.	6.9	31
83	Phosphoinositide 3â€kinaseÂÎ´is a regulatory Tâ€cell target in cancer immunotherapy. Immunology, 2019, 157, 210-218.	4.4	30
84	Immunodeficiency, autoimmune thrombocytopenia and enterocolitis caused by autosomal recessive deficiency of <i>PIK3CD</i>-encoded phosphoinositide 3-kinase Î´. Haematologica, 2019, 104, e483-e486.	3.5	26
85	C5a impairs phagosomal maturation in the neutrophil through phosphoproteomic remodeling. JCI Insight, 2020, 5, .	5.0	26
86	Class IA PI3Ks regulate subcellular and functional dynamics of IDO1. EMBO Reports, 2020, 21, e49756.	4.5	24
87	Intravital Imaging of Adoptive T-Cell Morphology, Mobility and Trafficking Following Immune Checkpoint Inhibition in a Mouse Melanoma Model. Frontiers in Immunology, 2020, 11, 1514.	4.8	23
88	PI3K Signaling in B Cell and T Cell Biology. Frontiers in Immunology, 2014, 5, 557.	4.8	22
89	PI3KÎ´ promotes CD4⁺ Tâ€cell interactions with antigenâ€presenting cells by increasing LFAâ€1 binding to ICAMâ€1. Immunology and Cell Biology, 2016, 94, 486-495.	2.3	19
90	Loss of Phosphatidylinositol 3-Kinase Activity in Regulatory T Cells Leads to Neuronal Inflammation. Journal of Immunology, 2020, 205, 78-89.	0.8	18

#	Article	IF	Citations
91	Topoisomerase 2Î² mutation impairs early B-cell development. Blood, 2020, 135, 1497-1501.	1.4	18
92	Two Birds with One Stone: Dual p110Î´ and p110Î³ Inhibition. Chemistry and Biology, 2013, 20, 1309-1310.	6.0	17
93	Genetic or Pharmaceutical Blockade of Phosphoinositide 3-Kinase P110Î´ Prevents Chronic Rejection of Heart Allografts. PLoS ONE, 2012, 7, e32892.	2.5	13
94	Immunomodulation of Selective Naive T Cell Functions by p110Î´ Inactivation Improves the Outcome of Mismatched Cell Transplantation. Cell Reports, 2015, 10, 702-710.	6.4	12
95	PI3KÎ´ Forms Distinct Multiprotein Complexes at the TCR Signalosome in NaÃ¯ve and Differentiated CD4+ T Cells. Frontiers in Immunology, 2021, 12, 631271.	4.8	12
96	PI3K in T Cell Adhesion and Trafficking. Frontiers in Immunology, 2021, 12, 708908.	4.8	12
97	Proliferative signals mediated by CD28 superagonists require the exchange factor Vav1 but not phosphoinositide 3â€kinase in primary peripheral T cells. European Journal of Immunology, 2008, 38, 2528-2533.	2.9	11
98	Inhibition of Phosphoinositide-3-Kinase Signaling Promotes the Stem Cell State of Trophoblast. Stem Cells, 2019, 37, 1307-1318.	3.2	10
99	A Protocol for Construction of Gene Targeting Vectors and Generation of Homologous Recombinant Embryonic Stem Cells. Methods in Molecular Biology, 2013, 1064, 337-354.	0.9	9
100	Targeting PI3KÎ´ function for amelioration of murine chronic graft-versus-host disease. American Journal of Transplantation, 2019, 19, 1820-1830.	4.7	9
101	Non-Invasive Multiphoton Imaging of Islets Transplanted Into the Pinna of the NOD Mouse Ear Reveals the Immediate Effect of Anti-CD3 Treatment in Autoimmune Diabetes. Frontiers in Immunology, 2018, 9, 1006.	4.8	8
102	The GPCR adaptor protein norbin suppresses the neutrophil-mediated immunity of mice to pneumococcal infection. Blood Advances, 2021, 5, 3076-3091.	5.2	8
103	Oncogenic PI3KÎ± promotes multipotency in breast epithelial cells. Science Signaling, 2015, 8, pe3.	3.6	4
104	Inhibition of Phosphoinositide 3-Kinase p110delta Does Not Affect T Cell Driven Development of Type 1 Diabetes Despite Significant Effects on Cytokine Production. PLoS ONE, 2016, 11, e0146516.	2.5	4
105	Activated PI3KÎ´ syndrome, an immunodeficiency disorder, leads to sensorimotor deficits recapitulated in a murine model. Brain, Behavior, & Immunity - Health, 2021, 18, 100377.	2.5	4
106	Acute Streptococcus pneumoniae lung infection: Mouse model and characterisation of the immune response.. Protocol Exchange, 0, , .	0.3	3
107	A cell-based bioluminescence assay reveals dose-dependent and contextual repression of AP-1-driven gene expression by BACH2. Scientific Reports, 2020, 10, 18902.	3.3	2
108	PI3K p110Î´ Is Expressed by gp38â^'CD31+ and gp38+CD31+ Spleen Stromal Cells and Regulates Their CCL19, CCL21, and LTÎ²R mRNA Levels. PLoS ONE, 2013, 8, e72960.	2.5	2

#	Article	IF	Citations
109	Editorial: Lipid Signaling in T Cell Development and Function. Frontiers in Immunology, 2015, 6, 410.	4.8	1
110	T5â€…Complement protein c5a induces prolonged neutrophil dysfunction in a clinically relevant model of human bacteraemia. , 2017, , .		1
111	How to resist PI3KÎ´ inhibition: activate MAPK!. Blood, 2021, 138, 3-4.	1.4	1
112	PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8⁺T cells. Journal of Cell Biology, 2012, 199, i8-i8.	5.2	1
113	Genetic or Pharmaceutical Blockade of Phosphoinositide 3-Kinase p110Î´ Prevents Chronic Rejection of Heart Allografts. Transplantation, 2012, 94, 301.	1.0	0
114	Genetic or Pharmaceutical Blockade of Phosphoinositide 3-Kinase p110Î´ Prevents Chronic Rejection of Heart Allografts. Transplantation, 2012, 94, 443.	1.0	0
115	MO064TISSUE-RESIDENT B CELLS DETERMINE SUSCEPTIBILITY TO URINARY TRACT INFECTION BY ORCHESTRATING MACROPHAGE POLARISATION. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
116	CD28. The AFCS-nature Molecule Pages, 0, , .	0.2	0
117	Abstract A86: Inactivation of p110delta PI3K releases potent antitumor immunity.. , 2013, , .		0
118	PI3K. , 2014, , 851-854.		0